Skip to content

Zymeworks ZYME Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options

Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$19.48M+715%
Summit Therapeutics logo
Summit TherapeuticsSMMT

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Zymeworks (ZYME) reported proceeds from issuance of shares under incentive and share based compensation plans including stock options of $8.72M in Q1 2026.
How has Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options changed year-over-year?
Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options increased by 1029.1% year-over-year, from $772K to $8.72M.
What is the long-term trend for Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options?
Over 3 years (2022 to 2025), Zymeworks's proceeds from issuance of shares under incentive and share based compensation plans including stock options has grown at a 304.7% compound annual growth rate (CAGR), from $255K to $16.9M.
What does proceeds from issuance of shares under incentive and share based compensation plans including stock options mean?
Captures cash inflows resulting from employees or directors exercising stock options or purchasing shares through incentive plans. It reflects the alignment of employee interests with shareholders and provides a supplemental source of liquidity.